Fresenius Biotech obtains reimbursement approval for Removab® antibody in Belgium
Removab® receives approval for a shorter infusion time in treating malignant ascites – one-year survival rate in Removab®-treated patients is more than four times higher
Fresenius Biotech obtains reimbursement approval for Removab® antibody in Italy
Fresenius Biotech develops and markets biopharma-ceuticals for the effective treatment of severe diseases.
ATG Fresenius® S
, a polyclonal antibody, is successfully marketed in over 60 countries.
We develop and market innovative antibody therapies for the treatment of cancer. We recently launched Removab®
, a trifunctional antibody indicated for the treatment of malignant ascites.